Comparison of biochemical data, blood pressure and physical activity between longevity and non-longevity districts in Japan

Circulation Journal

Volumn 72, Issue 10, 2008, Pages 1680-1684

  Mori, Ichiro ^a   Ishizuka, Tatsuo ^a   Morita, Hiroyuki ^a   Matsumoto, Masami ^a   Uno, Yoshihiro ^a   Kajita, Kazuo ^a   Ikeda, Takahide ^a   Fujioka, Kei ^a   Matsubara, Kenji ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Aging; Blood pressure; Diabetes mellitus; Hypertension

Indexed keywords

ADIPONECTIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PRASTERONE SULFATE; TRIACYLGLYCEROL;

ADULT; AGED; ANDROGEN BLOOD LEVEL; ARTICLE; BLOOD PRESSURE MEASUREMENT; CHOLESTEROL BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HEMOGLOBIN BLOOD LEVEL; HOMEOSTASIS; HUMAN; JAPAN; JAPANESE; LIFESPAN; LONGEVITY; MALE; PHYSICAL ACTIVITY; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPOSE TISSUE; AGED; BLOOD PRESSURE; BODY HEIGHT; BODY WEIGHT; BONE DENSITY; DIASTOLE; EXERCISE; FEMALE; GEOGRAPHY; GLUCOSE TOLERANCE TEST; HUMANS; JAPAN; LONGEVITY; MALE; MIDDLE AGED; MOTOR ACTIVITY; PULSE; SYSTOLE;

EID: 52749094558     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-07-1081     Document Type: Article

References (27)

1. Roth GS, Lane MA, Ingram DK, Mattison JA, Elahi D, Tobin JD, et al. Biomarkers of caloric restriction may predict longevity in humans. Science 2002; 297: 811.
2. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, et al for the United Kingdom prospective Disease Study Group. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998; 316: 823-828.
3. Sone H, Mizuno S, Fujii H, Fujii H, Yoshimura Y, Yamasaki Y, et al; Japan Diabetes Complication Study. Is the diagnosis of metabolic syndrome useful for predicting cardiovascular disease in Asian diabetic patients. Diabetes Care 2005; 28: 1463-1471.
4. Kitamura A, Iso H, Iida M, Naito Y, Sato S, Jacob DR, et al. Trends in the incidence of coronary heart disease and stroke and the prevalence of cardiovascular risk factors among Japanese men from 1963-1994. Am J Med 2002; 112: 104-109.
5. Keech A, Simes RJ, Barter P, Best J, Scott R, Takinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9796 people with type2 diabetes mellitus (the FIELD study): Randomized controlled trial. Lancet 2005; 366: 1849-1861.
6. Waki H, Yamauchi T, Kamon J, Ito Y, Uchida S, Kita S, et al. Impaired multimerization of human adiponectin mutants associated with diabetes: Molecular structure and multimer formation of adiponectin. J Biol Chem 2003; 278: 40352-40363.
7. Chasalow FI, Blethen SL, Duckett D, Zeitlin S, Greenfield J. Serum levels of dehydroepiandrosterone sulfate as determined by commercial kits and reagents. Steroids 1989; 54: 373-383.
8. Fukuhara S, Bito S, Green J, Hsiao A, Kurokawa K. Translation, adaptation, and validation of the SF-36 for use in Japan. J Clin Epidemiol 1998; 51: 1037-1044.
9. Fukuhara S, Ware JE, Kosinski M, Wada S, Gandek B. Psychometric and clinical tests of validity of the Japanse SF-36 healthy survey. J Clin Epidemiol 1998; 51: 1045-1053.
10. Podsiadlo D, Richardson S. The timed "Up & Go": A test of basic functional mobility for frail elderly person. J Am Geriatr Soc 1991; 39: 142-148.
11. Hashidate H, Uchiyama Y. Usefulness of functional gait reserve relative to activities of daily living in the elderly people. Jpn J Geriatr 2007; 44: 367-374.
12. World Health Organization: Diabetes mellitus: Report of a WHO Study Group (Tech. Rep. Ser. no. 727). Geneva: WHO, 1985.
13. PROGRESS Collaborative Study Group. Randomized trial of perindopril based blood pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-1041.
14. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7: 941-946.
15. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83.
16. Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class: A scavemger receptor expression in human-monocytes-derived macrophages. Circulation 2001; 103: 1057-1063.
17. Komura N, Kihara S, Sonoda M, Kumada M, Fujita K, Hiuge A, et al; the Osaka CAD group. Clinical significance of high-molecular weight form of adiponectin in male patients with coronary artery disease. Circ J 2007; 72: 23-28.
18. Otsuka F, Sugiyama S, Kojima S, Maruyoshi H, Funahashi T, Sakamoto T, et al. Hypoadiponectinemia is associated with impaired glucose tolerance and coronary artery disease in non-diabetic men. Circ J 2007; 71: 1703-1709.
19. Sparanger J, Krohe A, Mohlig M. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2001; 103: 1057-1063.
20. Hara K, Horikoshi M, Yamauchi T, Yago H, Miyazaki O, Ebinuma H, et al. Adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 2006; 29: 1357-1362.
21. Hulthe J, Hulten LM, Fagerberg B. Low adipocytes-derived plasma protein adiponectin concentrations are associated with metabolic syndrome and small dense low density lipoprotein particles: Atherosclerosis and insulin resistance study. Metabolism 2003; 52: 1612-1614.
22. Melby JC. Assessment of adrenocortical function. N Engl J Med 1970; 285: 735-739.
23. Gordon GB, Bush DE, Weisman HF. Reduction of atherosclerosis by administration of dehydroepiandrosterone. J Clin Invest 1988; 82: 712-720.
24. Yen TT, Allan JA, Pearson DV, Acton JM, Greenberg MM. Prevention of obesity in Avy/a mice by dehydroepiandrosterone. Lipid 1977; 12: 409-413.
25. Coleman DL, Schwizer RW, Leithr EH. Effect of genetic background on the therapeutic effects of dehydroepiandrosterone (DHEA) in diabetes-obesity mutants and aged normal mice. Diabetes 1984; 33: 26-32.
26. Ishizuka T, Kajita K, Miura A, Ishizawa M, Kanoh Y, Itaya S, et al. Dehydroepiandrosterone improves glucose uptake via activations of protein kinase C and phosphatidylinositol 3-kinase. Am J Physiol 1999; 276: E196-E204.
27. Matsumoto M, Ishizuka T, Kajita K, Sugiyama C, Morita H, Uno Y, et al. Dehydroepiandrosterone-sulfate concentration in men from a Japanese longevity district. Geriatr Gerontol Int 2007; 7: 352-356.